Unicycive Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports a Nasdaq listing compliance matter. The earliest reported event occurred on February 1, 2023; the filing was signed and dated February 7, 2023. Unicycive’s common stock trades under the symbol UNCY on the Nasdaq Capital Market.
Key Financial and Listing Metrics
- Nasdaq minimum bid-price requirement: $1.00 per share for continued listing.
- Stockholders’ equity requirement referenced for eligibility for a second compliance period: $5.0 million.
- Reported stockholders’ equity as of September 30, 2022: approximately $4.626 million.
- The filing does not provide revenue, net income, cash flow, margins, debt, cash balances, or liquidity metrics.
Material Changes Versus the Prior Period
On August 8, 2022, Nasdaq notified the Company that its common stock had closed below $1.00 per share for 30 consecutive business days. The Company received 180 calendar days, through January 30, 2023, to regain compliance. On February 1, 2023, Nasdaq notified the Company that compliance had not been regained and that the Company was not eligible for a second 180-day compliance period because its stockholders’ equity was below the $5.0 million initial-listing requirement for the Nasdaq Capital Market.
Outlook, Risks, Contingencies, and Unusual Items
- Nasdaq stated that the common stock would be subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel.
- The Company requested the hearing, which stays delisting action at least until the Panel issues a decision and any granted extension period expires.
- The hearing was scheduled for March 23, 2023.
- The Company planned to present a compliance plan and request additional time to satisfy the minimum bid-price requirement.
- The Panel could grant an extension through no later than August 8, 2023.
- The common stock was expected to continue trading on Nasdaq under “UNCY” at least while the hearing process remained pending.
Important Facts for Investors to Verify
- Whether the Nasdaq Hearings Panel granted an extension or imposed other conditions.
- Whether Unicycive subsequently regained compliance with the $1.00 minimum bid-price requirement.
- Whether the Company’s stockholders’ equity exceeded the applicable Nasdaq threshold.
- Any subsequent Nasdaq delisting determination or change in the trading venue for UNCY.
- The Company’s cash runway, financing needs, and other financial condition, which are not provided in this filing.